Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 46 entries
Sorted by: Best Match Show Resources per page
Correction: Blindness and Glaucoma: A Multicenter Data Review from 7 Academic Eye Clinics.

PloS one

Rossetti L, Digiuni M, Montesano G, Centofanti M, Fea AM, Iester M, Frezzotti P, Figus M, Ferreras A, Oddone F, Tanga L, Rolle T, Battaglino V, Posarelli C, Motolese I, Mittica P, Bagaglia SA, Menicacci C, De Cilla' S, Autelitano A, Fogagnolo P.
PMID: 26934677
PLoS One. 2016 Mar 02;11(3):e0151010. doi: 10.1371/journal.pone.0151010. eCollection 2016.

No abstract available.

Cite
Rossetti L, Digiuni M, Montesano G, et al. Correction: Blindness and Glaucoma: A Multicenter Data Review from 7 Academic Eye Clinics. PLoS One. 2016;11(3):e0151010doi: 10.1371/journal.pone.0151010.
Rossetti, L., Digiuni, M., Montesano, G., Centofanti, M., Fea, A. M., Iester, M., Frezzotti, P., Figus, M., Ferreras, A., Oddone, F., Tanga, L., Rolle, T., Battaglino, V., Posarelli, C., Motolese, I., Mittica, P., Bagaglia, S. A., Menicacci, C., De Cilla', S., Autelitano, A., & Fogagnolo, P. (2016). Correction: Blindness and Glaucoma: A Multicenter Data Review from 7 Academic Eye Clinics. PloS one, 11(3), e0151010. https://doi.org/10.1371/journal.pone.0151010
Rossetti, Luca, et al. "Correction: Blindness and Glaucoma: A Multicenter Data Review from 7 Academic Eye Clinics." PloS one vol. 11,3 (2016): e0151010. doi: https://doi.org/10.1371/journal.pone.0151010
Rossetti L, Digiuni M, Montesano G, Centofanti M, Fea AM, Iester M, Frezzotti P, Figus M, Ferreras A, Oddone F, Tanga L, Rolle T, Battaglino V, Posarelli C, Motolese I, Mittica P, Bagaglia SA, Menicacci C, De Cilla' S, Autelitano A, Fogagnolo P. Correction: Blindness and Glaucoma: A Multicenter Data Review from 7 Academic Eye Clinics. PLoS One. 2016 Mar 02;11(3):e0151010. doi: 10.1371/journal.pone.0151010. eCollection 2016. PMID: 26934677; PMCID: PMC4775056.
Copy Download .nbib Format: NLM
Antidepressant activity of fingolimod in mice.

Pharmacology research & perspectives

di Nuzzo L, Orlando R, Tognoli C, Di Pietro P, Bertini G, Miele J, Bucci D, Motolese M, Scaccianoce S, Caruso A, Mauro G, De Lucia C, Battaglia G, Bruno V, Fabene PF, Nicoletti F.
PMID: 26171219
Pharmacol Res Perspect. 2015 Jun;3(3):e00135. doi: 10.1002/prp2.135. Epub 2015 May 24.

Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDACs) and enhances the production of brain-derived neurotrophic factor (BDNF) in the CNS. Both...

Cite
di Nuzzo L, Orlando R, Tognoli C, et al. Antidepressant activity of fingolimod in mice. Pharmacol Res Perspect. 2015;3(3):e00135doi: 10.1002/prp2.135.
di Nuzzo, L., Orlando, R., Tognoli, C., Di Pietro, P., Bertini, G., Miele, J., Bucci, D., Motolese, M., Scaccianoce, S., Caruso, A., Mauro, G., De Lucia, C., Battaglia, G., Bruno, V., Fabene, P. F., & Nicoletti, F. (2015). Antidepressant activity of fingolimod in mice. Pharmacology research & perspectives, 3(3), e00135. https://doi.org/10.1002/prp2.135
di Nuzzo, Luigi, et al. "Antidepressant activity of fingolimod in mice." Pharmacology research & perspectives vol. 3,3 (2015): e00135. doi: https://doi.org/10.1002/prp2.135
di Nuzzo L, Orlando R, Tognoli C, Di Pietro P, Bertini G, Miele J, Bucci D, Motolese M, Scaccianoce S, Caruso A, Mauro G, De Lucia C, Battaglia G, Bruno V, Fabene PF, Nicoletti F. Antidepressant activity of fingolimod in mice. Pharmacol Res Perspect. 2015 Jun;3(3):e00135. doi: 10.1002/prp2.135. Epub 2015 May 24. PMID: 26171219; PMCID: PMC4492751.
Copy Download .nbib Format: NLM
Effects of the Calcium Antagonist Felodipine on Resting and Stress Testing Blood Pressure in Essential Hypertension.

American journal of therapeutics

Cardillo C, Mores N, Campia U, Musumeci V, Motolese M, Folli G.
PMID: 11835087
Am J Ther. 1994 Oct;1(3):198-205. doi: 10.1097/00045391-199410000-00005.

The current study analyzed the effects of different doses of the calcium channel blocker felodipine on cardiovascular response to a set of standardized laboratory tasks. We randomly allocated 21 essential hypertensive patients to receive extended release felodipine 5 mg,...

Cite
Cardillo C, Mores N, Campia U, et al. Effects of the Calcium Antagonist Felodipine on Resting and Stress Testing Blood Pressure in Essential Hypertension. Am J Ther. 1994;1(3):198-205doi: 10.1097/00045391-199410000-00005.
Cardillo, C., Mores, N., Campia, U., Musumeci, V., Motolese, M., & Folli, G. (1994). Effects of the Calcium Antagonist Felodipine on Resting and Stress Testing Blood Pressure in Essential Hypertension. American journal of therapeutics, 1(3), 198-205. https://doi.org/10.1097/00045391-199410000-00005
Cardillo, Carmine, et al. "Effects of the Calcium Antagonist Felodipine on Resting and Stress Testing Blood Pressure in Essential Hypertension." American journal of therapeutics vol. 1,3 (1994): 198-205. doi: https://doi.org/10.1097/00045391-199410000-00005
Cardillo C, Mores N, Campia U, Musumeci V, Motolese M, Folli G. Effects of the Calcium Antagonist Felodipine on Resting and Stress Testing Blood Pressure in Essential Hypertension. Am J Ther. 1994 Oct;1(3):198-205. doi: 10.1097/00045391-199410000-00005. PMID: 11835087.
Copy Download .nbib Format: NLM
Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems.

Journal of translational medicine

Galeffi P, Lombardi A, Pietraforte I, Novelli F, Di Donato M, Sperandei M, Tornambé A, Fraioli R, Martayan A, Natali PG, Benevolo M, Mottolese M, Ylera F, Cantale C, Giacomini P.
PMID: 17010186
J Transl Med. 2006 Sep 29;4:39. doi: 10.1186/1479-5876-4-39.

BACKGROUND: Aberrant signaling by ErbB-2 (HER 2, Neu), a member of the human Epidermal Growth Factor (EGF) receptor family, is associated with an aggressive clinical behaviour of carcinomas, particularly breast tumors. Antibodies targeting the ErbB-2 pathway are a preferred...

Cite
Galeffi P, Lombardi A, Pietraforte I, et al. Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. J Transl Med. 2006;4:39doi: 10.1186/1479-5876-4-39.
Galeffi, P., Lombardi, A., Pietraforte, I., Novelli, F., Di Donato, M., Sperandei, M., Tornambé, A., Fraioli, R., Martayan, A., Natali, P. G., Benevolo, M., Mottolese, M., Ylera, F., Cantale, C., & Giacomini, P. (2006). Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. Journal of translational medicine, 439. https://doi.org/10.1186/1479-5876-4-39
Galeffi, Patrizia, et al. "Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems." Journal of translational medicine vol. 4 (2006): 39. doi: https://doi.org/10.1186/1479-5876-4-39
Galeffi P, Lombardi A, Pietraforte I, Novelli F, Di Donato M, Sperandei M, Tornambé A, Fraioli R, Martayan A, Natali PG, Benevolo M, Mottolese M, Ylera F, Cantale C, Giacomini P. Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. J Transl Med. 2006 Sep 29;4:39. doi: 10.1186/1479-5876-4-39. PMID: 17010186; PMCID: PMC1592514.
Copy Download .nbib Format: NLM
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.

Oncotarget

Bon G, Loria R, Amoreo CA, Verdina A, Sperduti I, Mastrofrancesco A, Soddu S, Diodoro MG, Mottolese M, Todaro M, Stassi G, Milella M, De Maria R, Falcioni R.
PMID: 29312543
Oncotarget. 2016 Aug 19;8(65):108463-108479. doi: 10.18632/oncotarget.11400. eCollection 2017 Dec 12.

Although the medical treatment of colorectal cancer has evolved greatly in the last years, a significant portion of early-stage patients develops recurrence after therapies. The current clinical trials are directed to evaluate new drug combinations and treatment schedules. By...

Cite
Bon G, Loria R, Amoreo CA, et al. Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. Oncotarget. 2016;8(65):108463-108479doi: 10.18632/oncotarget.11400.
Bon, G., Loria, R., Amoreo, C. A., Verdina, A., Sperduti, I., Mastrofrancesco, A., Soddu, S., Diodoro, M. G., Mottolese, M., Todaro, M., Stassi, G., Milella, M., De Maria, R., & Falcioni, R. (2017). Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. Oncotarget, 8(65), 108463-108479. https://doi.org/10.18632/oncotarget.11400
Bon, Giulia, et al. "Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers." Oncotarget vol. 8,65 (2017): 108463-108479. doi: https://doi.org/10.18632/oncotarget.11400
Bon G, Loria R, Amoreo CA, Verdina A, Sperduti I, Mastrofrancesco A, Soddu S, Diodoro MG, Mottolese M, Todaro M, Stassi G, Milella M, De Maria R, Falcioni R. Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. Oncotarget. 2016 Aug 19;8(65):108463-108479. doi: 10.18632/oncotarget.11400. eCollection 2017 Dec 12. PMID: 29312543; PMCID: PMC5752456.
Copy Download .nbib Format: NLM
Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic Treatments.

Biomedicines

Li Pomi F, Macca L, Motolese A, Ingrasciotta Y, Berretta M, Guarneri C.
PMID: 34829823
Biomedicines. 2021 Nov 01;9(11). doi: 10.3390/biomedicines9111594.

Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease of the apocrine glands. It typically involves the axillary, submammary, genital, inguinal, perineal, and perianal regions. The development of abscesses, sinus tracts, and scars can lead to pain, scarring,...

Cite
Li Pomi F, Macca L, Motolese A, et al. Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic Treatments. Biomedicines. 2021;9(11)doi: 10.3390/biomedicines9111594.
Li Pomi, F., Macca, L., Motolese, A., Ingrasciotta, Y., Berretta, M., & Guarneri, C. (2021). Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic Treatments. Biomedicines, 9(11), . https://doi.org/10.3390/biomedicines9111594
Li Pomi, Federica, et al. "Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic Treatments." Biomedicines vol. 9,11 (2021). doi: https://doi.org/10.3390/biomedicines9111594
Li Pomi F, Macca L, Motolese A, Ingrasciotta Y, Berretta M, Guarneri C. Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic Treatments. Biomedicines. 2021 Nov 01;9(11). doi: 10.3390/biomedicines9111594. PMID: 34829823; PMCID: PMC8615387.
Copy Download .nbib Format: NLM
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Capone F, Lucchini M, Ferraro E, Bianco A, Rossi M, Cicia A, Cortese A, Cruciani A, De Arcangelis V, De Giglio L, Motolese F, Sancetta B, Mirabella M, Di Lazzaro V.
PMID: 34859382
Neurotherapeutics. 2021 Dec 03; doi: 10.1007/s13311-021-01165-9. Epub 2021 Dec 03.

The potential impact of disease-modifying therapies (DMTs) for multiple sclerosis (MS) on COVID-19 vaccination is poorly understood. According to recent observations, the humoral immune response could be impaired in patients treated with ocrelizumab or fingolimod. Our study evaluated the...

Cite
Capone F, Lucchini M, Ferraro E, et al. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics. 2021;doi: 10.1007/s13311-021-01165-9.
Capone, F., Lucchini, M., Ferraro, E., Bianco, A., Rossi, M., Cicia, A., Cortese, A., Cruciani, A., De Arcangelis, V., De Giglio, L., Motolese, F., Sancetta, B., Mirabella, M., & Di Lazzaro, V. (2021). Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, . https://doi.org/10.1007/s13311-021-01165-9
Capone, Fioravante, et al. "Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies." Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics vol. (2021). doi: https://doi.org/10.1007/s13311-021-01165-9
Capone F, Lucchini M, Ferraro E, Bianco A, Rossi M, Cicia A, Cortese A, Cruciani A, De Arcangelis V, De Giglio L, Motolese F, Sancetta B, Mirabella M, Di Lazzaro V. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics. 2021 Dec 03; doi: 10.1007/s13311-021-01165-9. Epub 2021 Dec 03. PMID: 34859382; PMCID: PMC8639214.
Copy Download .nbib Format: NLM
Beyond the skin involvement in Darier disease: A complicated neuropsychiatric phenotype.

Clinical case reports

Li Pomi F, Motolese A, Bertino L, Macca L, Arminio NC, Cardia R, Vaccaro M, Borgia F.
PMID: 34194784
Clin Case Rep. 2021 Jun 23;9(6):e04263. doi: 10.1002/ccr3.4263. eCollection 2021 Jun.

Psichiatric illness such as depression, schizophrenia and cognitive deficiency are frequently associated with the Darier Disease. Physicians should be aware of such association to allow prompt diagnosis and early interventions of potentially life-threatening psychiatric disorders.

Cite
Li Pomi F, Motolese A, Bertino L, et al. Beyond the skin involvement in Darier disease: A complicated neuropsychiatric phenotype. Clin Case Rep. 2021;9(6):e04263doi: 10.1002/ccr3.4263.
Li Pomi, F., Motolese, A., Bertino, L., Macca, L., Arminio, N. C., Cardia, R., Vaccaro, M., & Borgia, F. (2021). Beyond the skin involvement in Darier disease: A complicated neuropsychiatric phenotype. Clinical case reports, 9(6), e04263. https://doi.org/10.1002/ccr3.4263
Li Pomi, Federica, et al. "Beyond the skin involvement in Darier disease: A complicated neuropsychiatric phenotype." Clinical case reports vol. 9,6 (2021): e04263. doi: https://doi.org/10.1002/ccr3.4263
Li Pomi F, Motolese A, Bertino L, Macca L, Arminio NC, Cardia R, Vaccaro M, Borgia F. Beyond the skin involvement in Darier disease: A complicated neuropsychiatric phenotype. Clin Case Rep. 2021 Jun 23;9(6):e04263. doi: 10.1002/ccr3.4263. eCollection 2021 Jun. PMID: 34194784; PMCID: PMC8222748.
Copy Download .nbib Format: NLM
Ulcerative necrobiosis lipoidica: case report of an atypical presentation and literature review.

European review for medical and pharmacological sciences

Di Bartolomeo L, Macca L, Motolese A, Guarneri C, Guarneri F.
PMID: 34661264
Eur Rev Med Pharmacol Sci. 2021 Oct;25(19):6047-6050. doi: 10.26355/eurrev_202110_26882.

Necrobiosis lipoidica (NL) is a rare chronic granulomatous degenerative skin disease by unknown causes, which is mostly associated with diabetes mellitus, usually presenting with typical plaques of the shins. Although less common, some ulcerative forms may be seen in...

Cite
Di Bartolomeo L, Macca L, Motolese A, et al. Ulcerative necrobiosis lipoidica: case report of an atypical presentation and literature review. Eur Rev Med Pharmacol Sci. 2021;25(19):6047-6050doi: 10.26355/eurrev_202110_26882.
Di Bartolomeo, L., Macca, L., Motolese, A., Guarneri, C., & Guarneri, F. (2021). Ulcerative necrobiosis lipoidica: case report of an atypical presentation and literature review. European review for medical and pharmacological sciences, 25(19), 6047-6050. https://doi.org/10.26355/eurrev_202110_26882
Di Bartolomeo, L, et al. "Ulcerative necrobiosis lipoidica: case report of an atypical presentation and literature review." European review for medical and pharmacological sciences vol. 25,19 (2021): 6047-6050. doi: https://doi.org/10.26355/eurrev_202110_26882
Di Bartolomeo L, Macca L, Motolese A, Guarneri C, Guarneri F. Ulcerative necrobiosis lipoidica: case report of an atypical presentation and literature review. Eur Rev Med Pharmacol Sci. 2021 Oct;25(19):6047-6050. doi: 10.26355/eurrev_202110_26882. PMID: 34661264.
Copy Download .nbib Format: NLM
Metronidazole Encephalopathy EEG Features: A Case Report with Systematic Review of the Literature.

Brain sciences

Ricci L, Motolese F, Tombini M, Lanzone J, Rea R, Di Matteo F, Di Lazzaro V, Assenza G.
PMID: 32290116
Brain Sci. 2020 Apr 10;10(4). doi: 10.3390/brainsci10040227.

Metronidazole-induced encephalopathy (MIE) is a rare and often under-recognized iatrogenic condition. The diagnosis should be considered in metronidazole-treated patients presenting with acute encephalopathy, unprovoked seizures and cerebellar signs. While typical magnetic resonance imaging (MRI) findings strongly support the diagnosis,...

Cite
Ricci L, Motolese F, Tombini M, et al. Metronidazole Encephalopathy EEG Features: A Case Report with Systematic Review of the Literature. Brain Sci. 2020;10(4)doi: 10.3390/brainsci10040227.
Ricci, L., Motolese, F., Tombini, M., Lanzone, J., Rea, R., Di Matteo, F., Di Lazzaro, V., & Assenza, G. (2020). Metronidazole Encephalopathy EEG Features: A Case Report with Systematic Review of the Literature. Brain sciences, 10(4), . https://doi.org/10.3390/brainsci10040227
Ricci, Lorenzo, et al. "Metronidazole Encephalopathy EEG Features: A Case Report with Systematic Review of the Literature." Brain sciences vol. 10,4 (2020). doi: https://doi.org/10.3390/brainsci10040227
Ricci L, Motolese F, Tombini M, Lanzone J, Rea R, Di Matteo F, Di Lazzaro V, Assenza G. Metronidazole Encephalopathy EEG Features: A Case Report with Systematic Review of the Literature. Brain Sci. 2020 Apr 10;10(4). doi: 10.3390/brainsci10040227. PMID: 32290116; PMCID: PMC7226540.
Copy Download .nbib Format: NLM
New tools for shaping plasticity to enhance recovery after stroke.

Handbook of clinical neurology

Motolese F, Capone F, Di Lazzaro V.
PMID: 35034743
Handb Clin Neurol. 2022;184:299-315. doi: 10.1016/B978-0-12-819410-2.00016-3.

Stroke is the second most common cause of death worldwide and its prevalence is projected to increase in the coming years in parallel with the increase of life expectancy. Despite the great improvements in the management of the acute...

Cite
Motolese F, Capone F, Di Lazzaro V. New tools for shaping plasticity to enhance recovery after stroke. Handb Clin Neurol. 2022;184:299-315doi: 10.1016/B978-0-12-819410-2.00016-3.
Motolese, F., Capone, F., & Di Lazzaro, V. (2022). New tools for shaping plasticity to enhance recovery after stroke. Handbook of clinical neurology, 184299-315. https://doi.org/10.1016/B978-0-12-819410-2.00016-3
Motolese, Francesco, et al. "New tools for shaping plasticity to enhance recovery after stroke." Handbook of clinical neurology vol. 184 (2022): 299-315. doi: https://doi.org/10.1016/B978-0-12-819410-2.00016-3
Motolese F, Capone F, Di Lazzaro V. New tools for shaping plasticity to enhance recovery after stroke. Handb Clin Neurol. 2022;184:299-315. doi: 10.1016/B978-0-12-819410-2.00016-3. PMID: 35034743.
Copy Download .nbib Format: NLM
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis.

The Journal of dermatological treatment

Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Peccianti C, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavo SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Stingeni L, Caruso C, Argenziano G.
PMID: 32436765
J Dermatolog Treat. 2020 Jul 03;1-4. doi: 10.1080/09546634.2020.1773379. Epub 2020 Jul 03.

No abstract available.

Cite
Fargnoli MC, Esposito M, Ferrucci S, et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2020;1-4doi: 10.1080/09546634.2020.1773379.
Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Peccianti, C., Stinco, G., Zalaudek, I., Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, R., Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Stingeni, L., Caruso, C., & Argenziano, G. (2020). A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. The Journal of dermatological treatment, 1-4. https://doi.org/10.1080/09546634.2020.1773379
Fargnoli, M C, et al. "A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis." The Journal of dermatological treatment vol. (2020): 1-4. doi: https://doi.org/10.1080/09546634.2020.1773379
Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Peccianti C, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavo SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Stingeni L, Caruso C, Argenziano G. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2020 Jul 03;1-4. doi: 10.1080/09546634.2020.1773379. Epub 2020 Jul 03. PMID: 32436765.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 46 entries